Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Technology appraisal guidance
Reference number: TA375
Published:
Evidence
Review and download supporting evidence. Includes the full guideline if available.